Immunotherapy: past, present and future
By T. Waldmann. Nature Medicine, 2003
628 citations recorded by the source corpus.
Subfields: Immunology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/9c4755d36c0b5322e3ef3c2f70b4ce6818a3fe6c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- RNA therapeutics: Beyond RNA interference and antisense oligonucleotides (2012, background): “94 ), and although a single monoclonal antibody was approved by the FDA in 1986 the majority reached the market about 10 years late”
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis (2015, background): “The concept of immunosurveillance and involvement of the immune system in cancer development has been known for several years [2].”
- Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules (2011, background): “Among the existing targeted therapies, therapy with mAbs has the longest history, and, to date, over 25 therapeutic mAbs have been approved by the US Food and Drug Administratio”
- Cancer active targeting by nanoparticles: a comprehensive review of literature (2014, background): “Currently, there are several FDAapproved mAb therapies, with hundreds more undergoing clinical trials (Debbage 2009; Waldmann 2003).”
- Multifunctional cationic host defence peptides and their clinical applications (2011, background): “Because of the complex mechanisms of action and potential toxicities, most clinical trials have focussed on HDP treatment topically rather than systemically [19, 111].”
- Potent antibody therapeutics by design (2006, background): “Other important factors that contribute to the success of antibodies as drugs include better choices of antibody and target antigen for intervention in the pathobiology of diseas”
- The safety and side effects of monoclonal antibodies (2010, background): “This has led to mAbs having marked successes in the clini”